Figure 5. Effects of des-Arg⁹-bradykinin (DABK) and angiotensin II (ANG II) vascular smooth muscle cells (VSMC) growth.

[A] Aortic VSMC from Wistar rats treated with ANG II and/or DABK at low concentration (0.1 nM) in the presence or not of losartan (LOS – 10 µM), des-arg9-leu8-bradykinin (DAL – 10 µM) and TIRON (1 mM). Bar graph shows PCNA expression normalized against the housekeeping protein β-actin. Results are represented as mean±SEM of 4 experiments. *P<0.05 vs Vehicle. [B] Aortic VSMC from Wistar rats with ANG II at high concentration (100 nM) in the presence or not of losartan (LOS – 10 µM), des-arg9-leu8-bradykinin (DAL – 10 µM). Bar graph shows PCNA expression normalized against the housekeeping protein β-actin. Results are expressed as mean±SEM of 5 experiments. *P<0.05 vs vehicle. [C] [H3] leucine incorporation in VSMC treated with ANG II and/or DABK at low concentration (0.1 nM) in the presence or not of losartan (LOS – 10 µM) and des-arg9-leu8-bradykinin (DAL – 10 µM) and VSMC treated with ANG II at high concentration (100 nM). Results are expressed as mean±SEM of 3 experiments and *P<0.05 vs vehicle.